MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

MDT

96.36

-0.25%↓

A

137.13

-0.67%↓

VEEV

223.96

-0.48%↓

HQY

91.6

-1.53%↓

PHR.US

16.8

-0.3%↓

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

50.397

78.892

EPS

0.4

Dividendrendement

0.29

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+14.96% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.29%

2.38%

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

71M

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

16%

84%

13 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 dec 2025, 22:03 UTC

Belangrijke Marktbewegers

Mining Stocks Slip Near the End of Stellar Year

29 dec 2025, 15:57 UTC

Belangrijke Marktbewegers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Operate From Singapore

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec 2025, 23:37 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Integrate Manus Service Into Products

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec 2025, 23:35 UTC

Acquisities, Fusies, Overnames

Manus to Join Meta Platforms

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Raise Values Kraken at US$8.65 Billion

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin's Kraken Stake to Remain at 22.7%

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin: Additional Interest Offsets Dilution From Raise

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec 2025, 20:22 UTC

Marktinformatie

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec 2025, 20:02 UTC

Acquisities, Fusies, Overnames

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec 2025, 17:36 UTC

Marktinformatie

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

14.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.22 USD  14.96%

Hoogste 123 USD

Laagste 100 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

13 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat